Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Dyspnea | Research

One-session bilateral sequential whole lung lavage (OSBSWLL) for the management of pulmonary alveolar proteinosis

Authors: Javier Diaz-Mendoza, Eduardo Celis Valdiviezo, Niral M. Patel, Michael J. Simoff

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Whole Lung Lavage (WLL) has been an important part in the management of Pulmonary Alveolar Proteinosis (PAP) since it improves radiologic and clinical parameters. Bilateral WLL is usually performed in two sessions on different days. Few case reports have described one-session bilateral sequential lung lavage (OSBSWLL), and none have described ambulatory management (same-day discharge).

Methods

Demographic characteristics, physiologic parameters, procedure details and outcomes were retrospectively collected on consecutive patients who underwent OSBSWLL for PAP following an ambulatory protocol stablished in our institution.

Results

A total of 13 patients underwent 30 OSBSWLL (61.5% male; mean age 40). The mean SpO2 was 90% (IQR 9) and 94% (IQR 6), before and after OSBSWLL respectively. In 63.3% of cases, patients were discharged home the same day of procedure. Only in two cases (6.6%), patients required post-procedure prolonged mechanical ventilation (> 4 h) due to persistent hypoxia.

Conclusions

OSBSWLL can be performed with same-day discharge.
Literature
1.
go back to reference Gay P, Wallaert B, Nowak S, Yserbyt J, Stavros A, Hermant C, et al. Efficacy of whole-lung lavage in pulmonary alveolar proteinosis: a multicenter international study of GELF. Respiration. 2017;93(3):198–206.CrossRef Gay P, Wallaert B, Nowak S, Yserbyt J, Stavros A, Hermant C, et al. Efficacy of whole-lung lavage in pulmonary alveolar proteinosis: a multicenter international study of GELF. Respiration. 2017;93(3):198–206.CrossRef
2.
go back to reference Ben-Dov IKY, Rozman J, Soliman A, Bishara H, Zelligson E, Grief J, et al. Pulmonary alveolar proteinosis in Israel: ethnic clustering. Isr Med Assoc J. 1998;1:75–8. Ben-Dov IKY, Rozman J, Soliman A, Bishara H, Zelligson E, Grief J, et al. Pulmonary alveolar proteinosis in Israel: ethnic clustering. Isr Med Assoc J. 1998;1:75–8.
3.
go back to reference Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215–35.CrossRef Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215–35.CrossRef
4.
go back to reference Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest. 1997;111:460–6.CrossRef Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest. 1997;111:460–6.CrossRef
5.
go back to reference Lee KN, Levin DL, Webb WR, Chen D, Storto ML, Golden JA. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest. 1997;111:989–95.CrossRef Lee KN, Levin DL, Webb WR, Chen D, Storto ML, Golden JA. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest. 1997;111:989–95.CrossRef
6.
go back to reference Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527–39.CrossRef Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527–39.CrossRef
7.
go back to reference Ramirez J, Campbell GD. Pulmonary alveolar proteinosis. endobronchial treatment. Ann Intern Med. 1965;63:429–41.CrossRef Ramirez J, Campbell GD. Pulmonary alveolar proteinosis. endobronchial treatment. Ann Intern Med. 1965;63:429–41.CrossRef
8.
go back to reference Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, et al. WLL international study group a global survey on whole lung lavage in pulmonary alveolar proteinosis. Chest. 2016;150(1):251–3.CrossRef Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, et al. WLL international study group a global survey on whole lung lavage in pulmonary alveolar proteinosis. Chest. 2016;150(1):251–3.CrossRef
9.
go back to reference Stengel PW, Frazer DG, Weber KC. Lung degassing: an evaluation of two methods. J Appl Physiol Respir Environ Exerc Physiol. 1980;48(2):370–5.PubMed Stengel PW, Frazer DG, Weber KC. Lung degassing: an evaluation of two methods. J Appl Physiol Respir Environ Exerc Physiol. 1980;48(2):370–5.PubMed
10.
go back to reference Bonella F, Bauer PC, Griese M, Wessendorf TE, Guzman J, Costabel U. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. Eur Respir J. 2012;40:1468–74.CrossRef Bonella F, Bauer PC, Griese M, Wessendorf TE, Guzman J, Costabel U. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. Eur Respir J. 2012;40:1468–74.CrossRef
11.
go back to reference Abdelmalak BB, Khanna AK, Culver DA, Popovich MJ. Therapeutic whole lung lavage for pulmonary alveolar proteinosis: a procedural update. J Bronchology Interv Pulmonol. 2015;22(3):251–8.CrossRef Abdelmalak BB, Khanna AK, Culver DA, Popovich MJ. Therapeutic whole lung lavage for pulmonary alveolar proteinosis: a procedural update. J Bronchology Interv Pulmonol. 2015;22(3):251–8.CrossRef
Metadata
Title
One-session bilateral sequential whole lung lavage (OSBSWLL) for the management of pulmonary alveolar proteinosis
Authors
Javier Diaz-Mendoza
Eduardo Celis Valdiviezo
Niral M. Patel
Michael J. Simoff
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
Dyspnea
Dyspnea
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01734-w

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.